EUCTR2020-000627-40-BE进行中（未招募）1 期
Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial (IA-DUET)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Erasmus MC
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. 18 years or older
- •2. Have started or will start voriconazole or isavuconazole (or posaconazole if voriconazole or isavuconazole cannot be given as per treating physician’s decision) as antifungal therapy on the baseline visit.
- •3. For all patients: presence of one of the EORTC/MSG host factors as defined in appendix 1 or being admitted to the ICU with influenza
- •4. For non-ICU patients or ICU patients without influenza: Meet the EORTC/MSG clinical criterium (appendix 1)
- •5. For non-ICU patients or ICU patients without influenza: Meet the mycological criterium (appendix 1) or fulfil inclusion criterium 7
- •6. For ICU patients with influenza we consider an isolated positive sputum culture for Aspergillus spp. insufficient as a mycological criterium. Therefore, in these patients only one of the following mycological criteria are acceptable; Serum galactomannan ?0.5, BAL galactomannan ?1.0 or Aspergillus spp. cultured in BAL fluid.
- •7. Please note that patients with AML receiving chemotherapy or patients with ALL receiving or having received corticosteroid therapy within the last 4 weeks in the context of their pre-phase, induction, consolidation, intensification or interphase treatment as well as patients receiving systemic immunosuppressive therapy for GVHD can be included before the mycological criterium is fulfilled on condition that they fulfill the EORTC/MSG lung CT radiology criteria (halo sign, well-described nodule, cavity as described in appendix 1) at the time of inclusion and as long as the mycological test results are expected to become available within 96 and no later than 7 days after inclusion. If these test results turn out to be negative, the patient will be withdrawn from the study and further treatment is at physician’s discretion.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 350
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 300
排除标准
- •1. Known history of allergy, hypersensitivity or serious reaction to azole or echinocandin antifungals;
- •2. Patients with chronic invasive aspergillosis or a chronic non-invasive aspergillus infection (e.g. aspergilloma) defined as the clinical or radiological sign of infection being present for >28 days.
- •3. Receipt of itraconazole, voriconazole, posaconazole or isavuconazole as prophylaxis for at least 7 days in the 14 days preceding the date of the first radiological signs of the Aspergillus infection. Patients in which the most recent serum level of the triazole given as prophylaxis was subtherapeutic can be included (*).
- •4. Receipt of echinocandin prophylaxis for >96 hours in the preceding 7 days
- •5. Receipt of systemic antifungal treatment with an echinocandin or an azole for the current episode of invasive aspergillosis for a duration of > 96 hours.
- •6. For patients in the Netherlands only: Diagnostic testing to exclude azole resistance will not be possible (sputum cultures are negative and BAL sampling will not be performed)
- •7. ICU patients only: Patients with a sequential organ failure assessment (SOFA) score >11 at the time of screening for the study are excluded. If randomization is done >24 hours after screening the calculation should be repeated before the patient can be randomized (appendix 3)
- •8. ICU patients only: Patients in which weaning from the ventilator or ECMO system is deemed unlikely due to irreversible lung damage
- •9. Patients with any condition which, in the opinion of the investigator, could affect patient safety, preclude evaluation of response (e.g. because survival beyond 6 weeks is unlikely due to the underlying disease status)
- •10. Patient previously included in this study
研究者
相似试验
招募中
3 期
Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial (IA-DUET)Aspergillus infectioninvasive aspergillosis10017528NL-OMON52868Erasmus MC, Universitair Medisch Centrum Rotterdam325
进行中（未招募）
1 期
The IA-DUET study: A study on the usefulness of combination therapy for the treatment of an invasive fungal infection with Aspergillus.Invasive aspergillosisMedDRA version: 20.1Level: LLTClassification code 10022881Term: Invasive bronchopulmonary aspergillosisSystem Organ Class: 100000004862EUCTR2020-000627-40-NLErasmus MC650
终止
3 期
Azole-echinocandin Combination Therapy for Invasive AspergillosisInvasive AspergillosisNCT04876716Erasmus Medical Center66
已完成
不适用
inezolid for the Treatment of Suspected or Proven Gram-positive Infections: A Randomized, Open-label Trial Comparing Linezolid IV/PO and Teicoplanin IV or IM.-J18-L03-I38 Endocarditis, valve unspecifiedEndocarditis, valve unspecifiedI38J18L03PER-009-00PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
已完成
不适用
Combination therapy with azelnidipine or trichlormethiazide added on olmesartan in hypertensive patients with glucose intoleranceHypertension with glucose intoleranceJPRN-UMIN000003459Kanazawa Medical University Diabetes & Endocrinology40